Compare Inovio Pharmaceuticals Inc (INO) vs Marqeta Inc (MQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Marqeta Inc — how do they compare? Inovio Pharmaceuticals Inc trades at $1.1 (market cap $112.19M), while Marqeta Inc trades at $17.87 (market cap $1.82B). The key difference: Marqeta Inc is far larger — about 16.2× Inovio Pharmaceuticals Inc's market cap, and Marqeta Inc is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and Marqeta Inc for 44 Days on average.
| INO | MQ | |
|---|---|---|
Market Cap | $112.19M | $1.82B |
Volume | 3,201,278 | 1,126,466 |
Sector | Health | Technology |
52-Week High | $2.65 | $20.32 |
52-Week Low | $0.66 | $15.04 |
Typical Hold Time | 43 Days | 44 Days |
Enterprise Value | $83.51M | $1.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Inovio Pharmaceuticals (INO) trades at $1.09, down 5.63% today, reflecting ongoing financial challenges with minimal revenue of $65,340 in 2025 and substantial losses. The company shows consistent negative cash flow from operations but has beaten EPS estimates in recent quarters. Technical indicators are bearish, with moving averages and oscillators signaling selling pressure. Key near-term catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, its lead candidate for recurrent respiratory papillomatosis.
The investment case hinges on FDA approval of INO-3107, with analyst consensus target at $2.75 offering significant upside. However, high burn rate, negative margins, and dependence on financing pose substantial risks. Positive regulatory outcome could drive revaluation, but failure may exacerbate financial strain. Wall Street maintains cautious optimism with 59% buy ratings.
Marqeta (MQ) trades at $17.86, up 4.69% with a bullish technical outlook. The company shows improving fundamentals with three consecutive quarterly earnings beats and positive cash flow generation in 2025. Recent partnerships with BVNK for stablecoin cards and Google for kids' wallets highlight strategic growth initiatives. However, valuation remains elevated with a P/E of 193.83 and EV/EBITDA of 54.37 despite modest profitability metrics.
MQ presents a mixed investment case with strong operational momentum but premium valuation. The stock offers growth potential through expanding payment partnerships and product innovation, though faces risks from contract renewals and competitive pressure. Analyst consensus at $11.38 suggests caution despite recent positive earnings revisions and institutional interest in the fintech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Marqeta Inc
Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.
Read more on MQ →
